CoChat

Brexanolone for postpartum depression

Hutcherson, Timothy C, Cieri-Hutcherson, Nicole E, Gosciak, Meaghan F · 2020 · American Journal of Health-System Pharmacy

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

PURPOSE Postpartum depression (PPD) is defined as a major depressive episode occurring during pregnancy or within 4 weeks of delivery that may have significant consequences for mother and infant. Antidepressants are used to treat PPD, but their effectiveness may be limited by a slow time to peak effect. Brexanolone is Food and Drug Administration-approved for the management of PPD; its use requires patient participation in a risk evaluation and mitigation strategies (REMS) program. This review evaluates the efficacy and safety of brexanolone in PPD. SUMMARY Four completed studies, 1 quasi-experimental study and 3 randomized controlled trials (RCTs), were reviewed. Females who had moderate or severe PPD during the third trimester or within 4 weeks of delivery and were less than 6 months postpartum at initiation of therapy were included. Improvement in Hamilton Rating Scale for Depression (HAM-D) scores was assessed in addition to safety outcomes and scores on other depression rating scales. All studies demonstrated statistical improvement in HAM-D scores from baseline with brexanolone vs placebo use at the end of infusions (ie, hour 60). Results with regard to sustained HAM-D score improvements were mixed in the RCTs at 30-day follow-up. The most frequent adverse events in brexanolone-treated patients were sedation, dizziness, somnolence, and headache. The severe or serious adverse effect of presyncope, syncope, or loss of consciousness was reported by 4% of participants. CONC…

Overview

Integrity signals

Registry

Crossref · 10.1093/ajhp/zxz333

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Research works printed but not linked: 3

  1. 2018, Obstet Gynecol., e208
  2. Fitelson, 2011, Treatment of postpartum depression: clinical, psychological and pharmacological options, Int J Womens Health., 3, 1
  3. Zulresso [monograph]

Cited by

See all 29

Metadata

Authors
Hutcherson, T. C., Cieri-Hutcherson, N. E., & Gosciak, M. F.
Affiliations
  • D'Youville University (US)
  • University at Buffalo School of Pharmacy and Pharmaceutical Science, Buffalo, NY
Corresponding author
Hutcherson, Timothy C
Venue
American Journal of Health-System Pharmacy
Published
2020-02-19
Volume
77
Issue
5
Pages
336-345
ISSN
  • 1079-2082 (ISSN-L)
  • 1535-2900
OpenAlex
W3007171661
Cited by
25
References
40
Citations by year
2026: 6 · 2025: 8 · 2024: 1 · 2023: 6 · 2021: 3 · 2020: 1
FWCI
0.42
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Health-System Pharmacy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
Keywords
brexanolone, postpartum depression, intravenous fluid therapy, rapid onset of action, risk evaluation and mitigation strategy, adverse events, syncope, sedation, antidepressant efficacy, maternal mental health
MeSH terms
Risk Evaluation and Mitigation, Antidepressive Agents, Drug Combinations, Female, Humans, Pregnancy, Pregnanolone, Psychiatric Status Rating Scales, Severity of Illness Index, Randomized Controlled Trials as Topic, Depression, Postpartum, beta-Cyclodextrins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Brexanolone for postpartum depression. https://app.cochat.ai/papers/10.1093/ajhp/zxz333
The paper
Hutcherson, T. C., Cieri-Hutcherson, N. E., & Gosciak, M. F. (2020). Brexanolone for postpartum depression. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxz333

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.